Anchiano Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer.
Location: Israel, Jerusalem District, Jerusalem
Employees: 11-50
Total raised: $23M
Founded date: 2004
Investors 1
| Date | Name | Website |
| 26.10.2023 | Arc Ventur... | arc-vc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.04.2018 | - | $23M | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.03.2021 | ANCHIANO THERAPEUTICS LTD. : Other Events (form 8-K) | Item 8.01. Other Events. Supplemental Disclosures As previously disclosed, on December 14, 2020, Anchiano Therapeutics Ltd. ("Anchiano" or the "Company"), CMB Acquisition Ltd., an Israeli limited company and wholly-owned... |
| 02.02.2021 | Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis USA - English USA - English | |
| 05.01.2021 | Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients USA - English USA - English | |
| 08.01.2019 | Lilly to display drug pricing info on website; Catalent pledges $200M for its biologics unit | → Since the bipartisan bill compelling pharmaceutical companies to display drug prices as part of their television advertisements was torpedoed in September, the biopharma drug pricing controversy has only inten... |